The role of mTOR inhibitors in the management of posttransplant malignancy.
about
Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instabilityManagement of recurrent hepatocellular carcinoma after liver transplantIncidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosisUpdate on HHV-8-Associated MalignanciesCalcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centreRoles of the immune system in skin cancer.Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progressionA prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation.Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesGeneration of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.Long-term outcome after liver transplantation.Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.Mammalian target of rapamycin inhibition in hepatocellular carcinoma.Risk Factors for Melanoma in Renal Transplant Recipients.Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients.Resveratrol-mediated downregulation of Rictor attenuates autophagic process and suppresses UV-induced skin carcinogenesis.Living donor renal transplantation with incidental renal cell carcinoma from donor allograft.Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.Preclinical study of CC223 as a potential anti-ovarian cancer agent.First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.De novo malignant disease after liver transplantation? Risk and surveillance strategies.Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling.Combined liver-kidney transplantation in patients infected with human immunodeficiency virus.
P2860
Q24648173-6BC164F6-C1C6-4ADC-8EE3-6B2C26914C32Q26997063-1D3DD9C6-601C-4281-8C3E-78B7CEB40A8EQ27025406-2CAE2C4A-D788-4F6F-B191-4DFA575D04E2Q33814153-386CF2EC-31CC-43FC-BB1D-84526C755C96Q34009025-CC96D6AD-11E8-4886-B7CF-91C9B1DE3073Q34959580-DA78D842-5D7D-45C4-9813-EE811FFFB9F2Q35403714-FCC6954E-3E80-40D2-8928-15BAAE8EAE3DQ35884554-1F5E1A39-23DF-44E2-B385-D5A93E8AFC1AQ35973628-92EF4F7D-0B27-409C-9F0E-6D9AA96ADB44Q36183858-D89FD62B-6AF6-4C52-A373-D3303D77AF60Q36962089-99BBAD33-753D-417C-8F0D-C7E1A5AFE447Q37132788-8009FD3C-4113-45B5-9BE1-568F26A56EF8Q37450543-89656414-B8BE-4F48-B7EA-764488E5F89DQ37679263-ACBC6DE0-8247-44FB-9CFD-F18089C1C1A3Q38002368-79DF751A-831F-4BE2-ABBC-46859BAA3A5FQ38045000-0387812F-DF29-4FC4-9B2D-5EA67B674484Q38070693-83247E5F-E72B-44E3-A2AF-6AF364BF4BCCQ38268775-FA3BD0CB-C1BA-48C5-B184-20DFE8248A8CQ38271964-6B96C2B8-88E3-408D-A652-054CDFFC8C72Q38659989-F69F80A3-F26C-4A9E-AAD9-E8DD449B9B6DQ38682598-6AE9E820-2FE6-4B7F-A842-B68AF91E59C4Q38711763-D70C374C-E672-4027-9B18-56DB8870B22FQ38992157-B5DDB282-63E8-4E66-815E-46DCD83D7DF7Q39407091-E6CB7D42-5282-4B6F-B6B2-068607B0BDFBQ41300971-68E04589-F3A4-44BD-865E-142A041C2293Q41651902-C857DFB5-1272-4DF1-9FEC-5C20A17642ECQ41709197-44DF36B4-7164-4686-89DA-095D44F00EA0Q42460507-78E9AC77-6C5D-42CE-8F54-16980D768FC9Q43107477-4F646A4D-7A17-480B-851D-1209FC31CF8DQ43673379-9B22E0E8-21F0-4B00-B382-161FC4911793Q43857210-E3A5745F-4C02-4076-B987-88EEDBEACC68Q45175810-065CDD39-E953-4BD5-AC9D-BE188959F0DCQ45368130-0CF5D4B0-53CE-417B-9647-D5B79D5F79F3
P2860
The role of mTOR inhibitors in the management of posttransplant malignancy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of mTOR inhibitors in the management of posttransplant malignancy.
@en
The role of mTOR inhibitors in the management of posttransplant malignancy.
@nl
type
label
The role of mTOR inhibitors in the management of posttransplant malignancy.
@en
The role of mTOR inhibitors in the management of posttransplant malignancy.
@nl
prefLabel
The role of mTOR inhibitors in the management of posttransplant malignancy.
@en
The role of mTOR inhibitors in the management of posttransplant malignancy.
@nl
P1433
P1476
The role of mTOR inhibitors in the management of posttransplant malignancy.
@en
P2093
Anthony P Monaco
P304
P356
10.1097/TP.0B013E318193886E
P577
2009-01-01T00:00:00Z